Wide-Complex Tachycardia in a Patient on Flecainide: Rate Versus Rhythm Control Decision
A 57-year-old woman with paroxysmal atrial fibrillation and no structural heart disease (echo normal, LVEF 60%) has been on flecainide 100 mg twice daily and metoprolol for 2 years. She presents to the ED with palpitations and near-syncope. ECG shows a regular wide-complex tachycardia at 190 bpm with a right bundle branch block morphology and a superior axis. She is diaphoretic but alert, BP 96/60, and has a history of one prior episode of 'fast irregular heartbeat' that self-resolved. She is on no anticoagulant. The ED resident asks whether to give IV amiodarone and whether to cardiovert. Troponin is mildly elevated; potassium and magnesium are normal.
1. What is the leading diagnosis, and why is flecainide central to the safety analysis?
Read the worked answer
The leading diagnosis is flecainide-associated proarrhythmia, most concerning for 1:1 atrial flutter with class IC conduction slowing producing a wide-complex tachycardia, or ventricular tachycardia. Flecainide is a class IC agent that slows conduction and can organize atrial fibrillation into flutter and slow the flutter rate enough to permit 1:1 AV conduction, producing a rapid, wide (aberrated or pre-excited) complex tachycardia. It is also proarrhythmic in the setting of any structural disease or ischemia.
Key reasoning:
- 1:1 flutter at ~190-200 bpm with RBBB morphology and superior axis is a classic IC-flutter presentation; the wide QRS reflects rate-related aberration or baseline conduction disease.
- VT is possible and must be assumed until excluded; the prior 'fast irregular' episode may have been AF with rapid conduction.
- Flecainide must be stopped; continuing it or adding another antiarrhythmic without addressing the mechanism risks degeneration.
- Ischemia: mild troponin elevation in a wide-complex tachycardia can be demand-related, but ischemia can also precipitate the arrhythmia; this must be evaluated.
The judgment point: in a patient on a class IC drug with a new wide-complex tachycardia, the drug itself is a suspect and the rhythm may be an organized atrial arrhythmia with 1:1 conduction rather than VT.
2. The patient is hemodynamically borderline. Outline your immediate management, including what you would and would not give, with rationale.
Read the worked answer
Because she is borderline (BP 96/60, near-syncope, diaphoretic), treat as unstable wide-complex tachycardia:
- Synchronized cardioversion is appropriate if she deteriorates or fails to stabilize; do not delay for drug trials in an unstable patient.
- Avoid IV amiodarone as first-line here if the rhythm is IC-flutter: amiodarone can slow the flutter rate further and, in some cases, promote 1:1 conduction or worsen hemodynamics; more importantly, the priority is rate/rhythm control and removing the offending drug. Amiodarone is reasonable for confirmed VT but is not the reflex choice for suspected flecainide-related flutter.
- Avoid other class IC agents and avoid verapamil/diltiazem in a wide-complex rhythm of uncertain mechanism (risk of hemodynamic collapse if VT).
- Stop flecainide, obtain 12-lead during the event if possible, and consider adenosine only if you suspect a regular narrow/wide SVT and the patient is stable enough-diagnostically it can unmask flutter waves, but it will not terminate flutter and may cause transient AV block; use with caution.
- Sedate and cardiovert if unstable; if stable, consider cautious rate control and electrophysiology involvement.
- Evaluate for ischemia (serial troponins, ECG) and correct electrolytes.
The exam judgment: hemodynamic status drives the choice, and the drug history changes which antiarrhythmics are safe.
3. After stabilization, how do you counsel her about long-term rhythm strategy and anticoagulation?
Read the worked answer
Long-term plan:
- Discontinue flecainide permanently; document the proarrhythmia. If a class IC is ever reconsidered, it requires verified absence of structural disease and often concomitant AV-nodal blocking therapy, but given this event it should generally be avoided.
- Anticoagulation: she has AF and is not anticoagulated. Calculate CHA2DS2-VASc; even with a low score, the decision should be individualized and documented. If she has risk factors, start a DOAC (or warfarin) after assessing bleeding risk and renal function. Do not use aspirin as a substitute for anticoagulation when anticoagulation is indicated.
- Rhythm vs. rate control: given the proarrhythmia, a catheter ablation strategy for AF (pulmonary vein isolation) is attractive, especially if she is symptomatic and wants to avoid antiarrhythmics. Alternatively, rate control with a beta-blocker and reassessment.
- Avoid amiodarone long-term unless needed, given toxicity; if an antiarrhythmic is required, choose one appropriate for her (no structural disease) with monitoring.
- Education: teach her to recognize palpitations, near-syncope, and when to seek care; discuss driving restrictions per local rules after syncope/near-syncope.
Communication: explain that the drug that was meant to help likely caused this event, and frame ablation as a way to treat the underlying AF rather than relying on a drug that failed dangerously.